
  
    
      
        Background_NNP
        Mefloquine_NNP is_VBZ a_DT prophylactic_JJ antimalarial_NN drug_NN that_WDT is_VBZ
        also_RB used_VBN for_IN malaria_NN chemotherapy_NN ._. Adverse_JJ central_JJ nervous_JJ
        system_NN (_( CNS_NNP )_) events_NNS have_VBP been_VBN associated_VBN with_IN its_PRP$ use_NN [_NN 1_CD 2_CD
        ]_NN ._. Severe_NNP CNS_NNP events_NNS requiring_VBG hospitalization_NN occur_VB in_IN
        1_CD :_: 10_CD ,_, 000_CD and_CC 1_CD :_: 200_CD -_: 1200_CD patients_NNS taking_VBG mefloquine_NN for_IN
        chemoprophylaxis_NNS or_CC treatment_NN ,_, respectively_RB [_NN 1_CD 2_CD ]_NN ._.
        Milder_NNP CNS_NNP events_NNS (_( e_SYM ._. g_SYM ._. dizziness_NN ,_, headache_NN and_CC insomnia_NN )_)
        are_VBP a_DT more_RBR frequent_JJ occurrence_NN ,_, being_VBG experienced_VBN by_IN up_IN to_TO
        25_CD %_NN of_IN patients_NNS receiving_VBG chemoprophylactic_JJ doses_NNS and_CC 90_CD %_NN
        of_IN those_DT receiving_VBG therapeutic_JJ doses_NNS [_NN 1_CD 2_CD ]_NN ._. Higher_JJR blood_NN
        levels_NNS of_IN mefloquine_NN are_VBP reached_VBN under_IN therapeutic_JJ regimens_NNS
        (_( 2_CD ._. 1_LS -_: 23_CD μM_NN )_) compared_VBN with_IN those_DT for_IN prophylaxis_NNS (_( 3_CD ._. 8_CD μM_NN )_) [_NN
        3_CD 4_CD ]_NN ._. The_DT relative_JJ incidence_NN of_IN adverse_JJ effects_NNS is_VBZ ,_,
        therefore_RB ,_, probably_RB dose-related_JJ ,_, although_IN the_DT concomitant_NN
        effect_NN of_IN malaria_NN during_IN treatment_NN cannot_NN be_VB dismissed_VBN ._. It_PRP
        is_VBZ likely_JJ ,_, then_RB ,_, that_IN the_DT adverse_JJ neurological_JJ events_NNS
        associated_VBN with_IN mefloquine_NN have_VBP a_DT biochemical_JJ basis_NN ._.
        To_TO date_NN ,_, no_DT satisfactory_JJ biochemical_JJ explanation_NN of_IN the_DT
        neurotoxicity_NN of_IN mefloquine_NN has_VBZ been_VBN proposed_VBN ._. However_RB ,_, two_CD
        lines_NNS of_IN evidence_NN suggest_VBP that_IN the_DT endoplasmic_JJ reticulum_NN
        might_MD be_VB a_DT neuronal_NN target_NN of_IN mefloquine_NN ._. Go_VB and_CC others_NNS [_NN 5_CD
        6_CD ]_NN showed_VBD that_DT mefloquine_NN affects_VBZ calcium_NN flux_NN into_IN and_CC
        out_IN of_IN isolated_VBN mammalian_JJ microsomes_NNS obtained_VBN from_IN skeletal_NN
        muscle_NN and_CC neuronal_NN tissue_NN ._. These_DT observations_NNS suggest_VBP that_DT
        mefloquine_NN might_MD disrupt_VB ER_NNP calcium_NN homeostasis_NNS ,_, but_CC are_VBP
        difficult_JJ to_TO interpret_VB since_IN the_DT experiments_NNS were_VBD not_RB
        conducted_VBN in_IN an_DT intact_JJ cell_NN system_NN ._. In_IN an_DT unrelated_JJ study_NN ,_,
        we_PRP investigated_VBD the_DT effects_NNS of_IN mefloquine_NN on_IN global_JJ
        transcription_NN in_IN rat_NN neuroblastoma_NN (_( NG_NNP 108_CD )_) cells_NNS using_VBG
        microarrays_NNS [_NN 7_CD ]_NN ._. Mefloquine_NNP caused_VBD a_DT striking_JJ
        upregulation_NN of_IN growth_NN arrest_NN and_CC development_NN protein_NN 153_CD
        (_( GADD_NNP 153_CD )_) ,_, a_DT transcription_NN factor_NN selectively_RB modulated_JJ
        under_IN conditions_NNS of_IN ER_NNP stress_NN [_NN 8_CD ]_NN ._. Taken_VBN together_RB ,_, these_DT
        observations_NNS suggest_VBP that_DT mefloquine_NN might_MD perturb_NN the_DT
        function_NN of_IN the_DT ER_NNP via_IN a_DT disruption_NN of_IN calcium_NN homeostasis_NNS ._.
        Most_JJS ER-active_NNP agents_NNS (_( e_SYM ._. g_SYM ._. thapsigargin_NN and_CC ryanodine_NN )_)
        deplete_VB the_DT ER_NNP calcium_NN pool_NN either_CC by_IN (_( i_NNP )_) inhibiting_VBG the_DT ER_NNP
        calcium_NN pump_NN and_CC thereby_RB preventing_VBG the_DT replenishment_NN of_IN
        the_DT ER_NNP calcium_NN pool_NN or_CC (_( ii_NN )_) triggering_VBG ER_NNP (_( ryanodine_NN or_CC
        inositol_NN 1_CD ,_, 4_CD ,_, 5_CD -_: trisphosphate_NN (_( IP_NNP 
        3_LS )_) activated_VBN )_) calcium_NN release_NN channels_NNS
        [_NN 9_CD ]_NN ._. These_DT phenomena_NNS can_MD be_VB visualized_JJ by_IN fluorescence_NN
        microscopy_NN as_IN a_DT transient_JJ increase_NN in_IN cytoplasmic_JJ calcium_NN
        concentrations_NNS (_( for_IN example_NN see_VB [_NN 10_CD ]_NN )_) ._. Nominally_NNP
        calcium-free_JJ media_NNS are_VBP used_VBN so_IN that_IN the_DT effect_NN can_MD be_VB
        distinguished_VBN from_IN calcium_NN influx_NN mediated_JJ via_IN plasma_NN
        membrane_NN channels_NNS ._. If_IN the_DT test_NN agent_NN can_MD be_VB shown_VBN to_TO
        antagonize_VB the_DT release_NN of_IN calcium_NN by_IN a_DT known_VBN ER_NNP agonist_NN ,_, it_PRP
        can_MD then_RB be_VB concluded_VBN that_IN the_DT ER_NNP calcium_NN pool_NN is_VBZ a_DT target_NN
        of_IN the_DT compound_NN ._.
        ER_NNP function_NN is_VBZ critical_JJ if_IN protein_NN synthesis_NN and_CC folding_VBG
        is_VBZ to_TO successfully_RB occur_VB in_IN eukaryotic_JJ cells_NNS [_NN 11_CD 12_CD ]_NN ._. ER_NNP
        stress_NN ,_, induced_VBN by_IN cellular_JJ events_NNS as_RB diverse_JJ as_IN disrupted_VBN
        calcium_NN homeostasis_NNS ,_, elevated_VBD levels_NNS of_IN reactive_JJ oxygen_NN
        species_NNS and_CC viral_JJ infection_NN ,_, leads_VBZ to_TO accumulation_NN of_IN
        dysfunctional_NN ER_NNP chaperones_NNS and_CC misfolded_JJ proteins_NNS [_NN 11_CD ]_NN ._.
        Cells_NNP respond_VB by_IN one_CD or_CC both_DT of_IN two_CD conserved_JJ stress_NN
        response_NN pathways_NNS ._. The_DT first_JJ ,_, the_DT ER_NNP overload_NN response_NN ,_,
        triggers_VBZ the_DT activation_NN of_IN the_DT transcription_NN factor_NN NFkB_NNP
        and_CC the_DT subsequent_JJ upregulation_NN of_IN inflammatory_JJ proteins_NNS [_NN
        13_CD ]_NN ._. The_DT second_NN ,_, the_DT unfolded_VBD protein_NN response_NN (_( UPR_NNP )_)
        induces_VBZ three_CD divergent_JJ cellular_JJ events_NNS :_: (_( i_NNP )_) the_DT activation_NN
        of_IN transcription_NN factor_NN ATF_NNP 6_CD leading_VBG to_TO the_DT upregulation_NN of_IN
        ER_NNP chaperones_NNS such_JJ as_IN protein_NN disulfide_NN isomerase_NN ,_, (_( ii_NN )_)
        upregulation_NN of_IN the_DT pro-apoptotic_JJ transcription_NN factor_NN
        GADD_NNP 153_CD and_CC (_( iii_NN )_) suppression_NN of_IN protein_NN synthesis_NN via_IN
        phosphorylation_NN of_IN eukaryotic_JJ translation_NN initiation_NN factor_NN
        2_CD α_NN (_( eIF_NN 2_CD α_NN )_) by_IN pancreatic_JJ eIF_NN 2_CD α_NN kinase_NN (_( PEK_NNP /_NN PERK_NNP ,_, [_NN 11_CD 12_CD ]_NN
        )_) ._. Upregulation_NNP of_IN the_DT ER_NNP chaperones_NNS ,_, GADD_NNP 153_CD and_CC PERK_NNP in_IN
        response_NN to_TO a_DT toxic_JJ insult_NN would_MD constitute_VB direct_JJ evidence_NN
        of_IN an_DT ER_NNP stress_NN response_NN ._.
        In_IN the_DT present_JJ study_NN ,_, using_VBG laser_NN scanning_VBG confocal_NN
        microscopy_NN ,_, we_PRP show_VBP that_IN the_DT ER_NNP calcium_NN pool_NN is_VBZ a_DT target_NN of_IN
        mefloquine_NN in_IN rat_NN neurons_NNS ,_, as_RB ,_, under_IN calcium_NN free_JJ
        conditions_NNS ,_, the_DT drug_NN induces_VBZ elevations_NNS in_IN intracellular_NN
        calcium_NN concentrations_NNS and_CC antagonizes_NNS the_DT pharmacological_JJ
        effect_NN of_IN thapsigargin_NN ,_, a_DT known_VBN inhibitor_NN of_IN the_DT ER_NNP calcium_NN
        pump_NN ._. Further_RB ,_, we_PRP show_VBP that_IN ,_, in_IN the_DT presence_NN of_IN
        extra-neuronal_JJ calcium_NN ,_, mefloquine_NN induces_VBZ a_DT sustained_VBN
        elevation_NN of_IN cytoplasmic_JJ calcium_NN levels_NNS via_IN an_DT unknown_JJ
        mechanism_NN ._. The_DT disruption_NN of_IN calcium_NN homeostasis_NNS by_IN
        mefloquine_NN appears_VBZ to_TO be_VB related_VBN ,_, in_IN terms_NNS of_IN dose-effect_JJ
        and_CC kinetics_NNS of_IN action_NN ,_, to_TO the_DT acute_JJ neurotoxicity_NN of_IN the_DT
        drug_NN ._. In_IN a_DT microarray_NN study_NN we_PRP also_RB show_VBP that_DT mefloquine_NN
        induces_VBZ the_DT transcription_NN of_IN key_JJ ER_NNP stress_NN response_NN genes_NNS ._.
        Collectively_RB ,_, the_DT data_NNS suggest_VBP that_DT mefloquine_NN may_MD inhibit_VB
        neuronal_NN ER_NNP function_NN and_CC disrupt_VB neuronal_NN calcium_NN
        homeostasis_NNS at_IN physiologically_RB relevant_JJ concentrations_NNS 
        in_IN vitro_NN ._.
      
      
        Methods_NNP
        
          Materials_NNS
          Racemic_NNP (_( 
          erythro_NN )_) mefloquine_NN was_VBD obtained_VBN
          from_IN the_DT WRAIR_NNP chemical_NN inventory_NN system_NN ._. The_DT
          calcium-sensitive_JJ dye_NN Fluo_NNP 3_CD was_VBD purchased_VBN from_IN Molecular_NNP
          Probes_NNP ,_, Eugene_NNP ,_, OR_NNP ._. Reagents_NNP used_VBD in_IN cell_NN culture_NN and_CC
          neurotoxicity_NN /_NN neuroprotection_NN assays_NNS were_VBD obtained_VBN from_IN
          Sigma_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ._. Biosource_NNP International_NNP ,_, Rockville_NNP ,_,
          MD_NNP ,_, and_CC GIBCO_NNP /_NN Life_NNP Technologies_NNPS ,_, Grand_NNP Island_NNP ,_, NY_NNP ._.
        
        
          Preparation_NNP of_IN primary_JJ neuronal_NN cell_NN
          cultures_NNS
          Primary_JJ neuronal_NN cultures_NNS of_IN feotal_NN rat_NN forebrains_NNS
          were_VBD prepared_VBN as_IN described_VBN previously_RB [_NN 14_CD ]_NN ._. Briefly_NNP ,_,
          the_DT forebrains_NNS of_IN feotal_NN rat_NN pups_NNS (_( embryonic_JJ day_NN 15_CD )_) were_VBD
          isolated_VBN ,_, and_CC the_DT cells_NNS were_VBD dispersed_VBD by_IN repeated_VBN
          mechanical_JJ trituration_NN in_IN neuronal_NN culture_NN medium_NN (_( NCM_NNP =_SYM
          Ham_NNP 's_POS F-_NNP 12_CD :_: Basal_NNP Medium_NNP Eagle_NNP ,_, 1_CD :_: 1_CD ;_: supplemented_JJ with_IN
          dextrose_NN ,_, 0_CD ._. 6_CD g_SYM /_NN l_NN ;_: glutamine_NN ,_, 0_CD ._. 35_CD %_NN ;_: and_CC Pen-_NNP Strep_NNP ,_, 1_CD %_NN )_) ._.
          Following_VBG centrifugation_NN (_( 900_CD ×_NN g_SYM ;_: 5_CD min_NN )_) and_CC
          re-suspension_JJ in_IN fresh_JJ NCM_NNP ,_, the_DT cells_NNS were_VBD counted_VBN and_CC
          plated_JJ onto_IN poly-_NN L-_NNP lysine-coated_JJ 48_CD well_RB plates_NNS at_IN a_DT
          density_NN of_IN 0_CD ._. 5_CD ×_NN 10_CD 6_CD cells_NNS /_NN well_RB ._. For_IN imaging_NN experiments_NNS
          the_DT neurons_NNS were_VBD transferred_VBN to_TO 4_CD -_: chamber_NN cover_NN glass_NN
          slides_NNS that_WDT had_VBD been_VBN previously_RB coated_VBN with_IN poly-_NN L-_NNP lysine_NN
          followed_VBN by_IN collagen_NN ._. Each_DT chamber_NN contained_VBD 1_CD ×_NN 10_CD
          6_CD cells_NNS ._. For_IN the_DT array_NN studies_NNS ,_, the_DT neurons_NNS (_( 20_CD ×_NN 10_CD
          6_CD neurons_NNS per_IN flask_NN )_) were_VBD transferred_VBN to_TO 75_CD cm_NN 2_CD flasks_NNS ._. To_TO
          suppress_VB glial_NN growth_NN ,_, cultures_NNS were_VBD treated_VBN with_IN
          cytosine_NN β-_NN D-_NNP arabinofuranoside_NN (_( 10_CD -_: 5_CD M_NNP )_) after_IN 3_CD days_NNS 
          in_IN vitro_NN ._. All_DT cultures_NNS were_VBD
          maintained_VBN in_IN an_DT incubator_NN (_( 5_CD %_NN CO_NNP 
          2_CD ;_: 37_CD °_NN C_NNP )_) for_IN at_IN least_JJS 6_CD days_NNS and_CC no_RB
          more_JJR than_IN 10_CD days_NNS prior_RB to_TO use_VB ._.
        
        
          Confocal_NNP microscopy_NN
          The_DT approach_NN utilized_JJ for_IN confocal_NN microscopy_NN
          experiments_NNS is_VBZ similar_JJ to_TO that_DT employed_VBN in_IN an_DT earlier_JJR
          study_NN [_NN 14_CD ]_NN ._. Neurons_NNP (_( on_IN chamber_NN slides_NNS )_) were_VBD treated_VBN
          with_IN 5_CD μM_NN Fluo-_NNP 3_CD -_: AM_NNP for_IN 1_CD h_NN ._. After_IN 1_CD h_NN in_IN an_DT incubator_NN ,_,
          the_DT cells_NNS were_VBD rinsed_JJ with_IN fresh_JJ Mg_NNP 2_CD +_NN -_: free_JJ Locke_NNP 's_POS
          solution_NN (_( NaCl_NNP ,_, 154_CD mM_NN ;_: KCl_NNP ,_, 5_CD ._. 6_CD mM_NN ;_: NaHCO_NNP 
          3_CD ,_, 3_CD ._. 6_CD mM_NN ;_: CaCl_NNP 
          2_CD ,_, 2_CD ._. 3_CD mM_NN ;_: glucose_NN ,_, 5_CD ._. 6_CD mM_NN ;_: HEPES_NNP ,_, 5_CD
          mM_NN ;_: pH_NN 7_CD ._. 4_LS )_) ,_, and_CC returned_VBD to_TO the_DT incubator_NN for_IN an_DT
          additional_JJ 15_CD minutes_NNS prior_RB to_TO initiating_VBG the_DT imaging_NN
          experiments_NNS ._. Changes_NNS in_IN neuronal_NN calcium_NN homeostasis_NNS were_VBD
          monitored_VBN using_VBG a_DT Bio-_NNP Rad_NNP Radiance_NNP 2000_CD confocal_NN imaging_NN
          system_NN ._. Changes_NNS in_IN cytoplasmic_JJ calcium_NN were_VBD recorded_VBN as_IN
          fluctuations_NNS in_IN the_DT emitted_VBN fluorescence_NN of_IN
          Fluo-_NNP 3_CD -_: complexed_JJ calcium_NN at_IN 530_CD nm_NN (_( excitation_NN was_VBD 488_CD
          nm_NN )_) ._. Sequential_NNP image_NN scans_NNS of_IN fields_NNS containing_VBG 5_CD -_: 25_CD
          neurons_NNS were_VBD used_VBN to_TO construct_VB temporal_JJ profiles_NNS of_IN the_DT
          effects_NNS of_IN the_DT different_JJ agonists_NNS ._. Typically_RB ,_, scans_NNS were_VBD
          made_VBN at_IN 10_CD or_CC 15_CD s_VBZ intervals_NNS ._. To_TO compare_VB the_DT fluorescence_NN
          levels_NNS in_IN different_JJ neurons_NNS (_( which_WDT were_VBD often_RB in_IN slightly_RB
          different_JJ focal_JJ planes_NNS )_) on_IN different_JJ days_NNS ,_, the_DT
          fluorescence_NN readings_NNS at_IN each_DT time_NN point_NN were_VBD normalized_JJ
          to_TO the_DT first_JJ one_CD taken_VBN for_IN each_DT neuron_NN ._.
        
        
          Effects_NNPS of_IN mefloquine_NN on_IN ER_NNP calcium_NN
          homeostasis_NNS
          In_IN the_DT first_JJ series_NN of_IN experiments_NNS ,_, mefloquine_NN 's_POS
          effects_NNS on_IN mobilization_NN of_IN ER_NNP calcium_NN stores_NNS were_VBD
          investigated_VBN ._. The_DT neurons_NNS (_( chamber_NN slides_NNS )_) were_VBD rinsed_JJ
          twice_RB with_IN fresh_JJ low_JJ calcium_NN Locke_NNP 's_POS buffer_NN (_( NaCl_NNP ,_, 154_CD
          mM_NN ;_: KCl_NNP ,_, 5_CD ._. 6_CD mM_NN ;_: NaHCO_NNP 
          3_CD ,_, 3_CD ._. 6_CD mM_NN ;_: CaCl_NNP 
          2_CD ,_, 0_CD ._. 92_CD mM_NN ;_: glucose_NN ,_, 5_CD ._. 6_CD mM_NN ;_: HEPES_NNP ,_, 5_CD
          mM_NN ;_: EGTA_NNP ,_, 1_CD mM_NN ;_: pH_NN 7_CD ._. 4_LS )_) and_CC immersed_VBN in_IN the_DT same_JJ solution_NN
          (_( 240_CD μl_NN per_IN chamber_NN )_) ._. Neurons_NNP were_VBD scanned_JJ at_IN 10_CD s_VBZ
          intervals_NNS ._. Mefloquine_NNP (_( final_JJ concentration_NN of_IN 80_CD μM_NN )_) or_CC
          DMSO_NNP (_( 0_CD ._. 2_LS %_NN )_) ,_, thapsigargin_NN (_( 1_CD μM_NN )_) ,_, glutamate_NN (_( 1_CD μM_NN )_) and_CC
          CaCl_NNP 
          2_CD (_( 1_CD ._. 6_CD mM_NN )_) ,_, were_VBD added_VBN after_IN scans_VBZ 3_CD ,_,
          33_CD ,_, 63_CD and_CC 67_CD respectively_RB ._. All_DT drugs_NNS were_VBD prepared_VBN in_IN
          calcium-free_JJ Locke_NNP 's_POS solution_NN containing_VBG no_DT EGTA_NNP ._. Data_NNP
          analysis_NN was_VBD conducted_VBN only_RB for_IN neurons_NNS in_IN which_WDT an_DT
          increase_NN in_IN cytoplasmic_JJ calcium_NN was_VBD observed_VBN after_IN the_DT
          addition_NN of_IN calcium_NN chloride_NN ._.
        
        
          Effects_NNPS of_IN lower_JJR mefloquine_NN doses_NNS on_IN ER_NNP calcium_NN
          homeostasis_NNS
          In_IN a_DT second_JJ series_NN of_IN experiments_NNS ,_, the_DT effects_NNS of_IN
          lower_JJR mefloquine_NN doses_NNS on_IN ER_NNP calcium_NN homeostasis_NNS were_VBD
          investigated_VBN ._. The_DT neurons_NNS (_( chamber_NN slides_NNS )_) were_VBD rinsed_JJ
          twice_RB with_IN fresh_JJ low_JJ calcium_NN Locke_NNP 's_POS buffer_NN containing_VBG
          DMSO_NNP (_( NaCl_NNP ,_, 154_CD mM_NN ;_: KCl_NNP ,_, 5_CD ._. 6_CD mM_NN ;_: NaHCO_NNP 
          3_CD ,_, 3_CD ._. 6_CD mM_NN ;_: CaCl_NNP 
          2_CD ,_, 0_CD ._. 92_CD mM_NN ;_: glucose_NN ,_, 5_CD ._. 6_CD mM_NN ;_: HEPES_NNP ,_, 5_CD
          mM_NN ;_: EGTA_NNP ,_, 1_CD mM_NN ;_: DMSO_NNP ,_, 0_CD ._. 625_CD %_NN ;_: pH_NN 7_CD ._. 4_LS )_) and_CC immersed_VBN in_IN the_DT
          same_JJ solution_NN (_( 240_CD μl_NN per_IN chamber_NN )_) ._. Neurons_NNP were_VBD scanned_JJ
          at_IN 10_CD s_VBZ intervals_NNS ._. Mefloquine_NNP (_( 2_CD ,_, 10_CD ,_, 30_CD ,_, 60_CD ,_, 80_CD or_CC 200_CD
          μM_NN )_) ,_, thapsigargin_NN (_( 1_CD μM_NN )_) ,_, glutamate_NN (_( 1_CD μM_NN )_) and_CC CaCl_NNP 
          2_CD (_( 1_CD ._. 6_CD mM_NN final_JJ concentration_NN )_) were_VBD
          added_VBN sequentially_RB as_IN outlined_VBN earlier_RBR ,_, except_IN that_DT for_IN
          the_DT lowest_JJS mefloquine_NN dose_NN experiment_NN ,_, 2_CD and_CC 10_CD μM_NN
          mefloquine_NN were_VBD added_VBN to_TO the_DT same_JJ well_RB after_IN scans_VBZ 3_CD and_CC
          18_CD respectively_RB ._. Selection_NN of_IN neurons_NNS for_IN data_NNS analysis_NN
          was_VBD conducted_VBN as_IN described_VBN above_IN ._. For_IN each_DT mefloquine_NN
          concentration_NN in_IN each_DT experiment_NN ,_, the_DT maximum_NN increase_NN in_IN
          the_DT cytoplasmic_JJ calcium_NN concentration_NN relative_JJ to_TO the_DT
          baseline_NN was_VBD determined_VBN (_( at_IN least_JJS four_CD replicate_VB
          experiments_NNS were_VBD conducted_VBN for_IN each_DT mefloquine_NN
          concentration_NN )_) ._. For_IN example_NN ,_, the_DT maximum_NN relative_JJ
          increase_NN in_IN cytoplasmic_JJ calcium_NN concentration_NN induced_VBN by_IN
          mefloquine_NN at_IN 80_CD μM_NN in_IN one_CD of_IN the_DT experiments_NNS was_VBD 2_CD ._. 95_CD ,_,
          as_IN illustrated_VBN in_IN Figure_NN 1_CD ._. Concentration-response_NNP
          effects_NNS were_VBD then_RB expressed_VBN as_IN a_DT percentage_NN change_NN in_IN
          terms_NNS of_IN the_DT mean_JJ relative_JJ increase_NN in_IN cytoplasmic_JJ
          calcium_NN observed_VBD at_IN the_DT highest_JJS mefloquine_NN concentration_NN ._.
          The_DT highest_JJS mefloquine_NN concentration_NN used_VBN was_VBD 200_CD μM_NN ,_,
          since_IN this_DT was_VBD the_DT lowest_JJS concentration_NN tested_VBN that_WDT
          induced_VBD almost_RB 100_CD %_NN loss_NN of_IN viability_NN after_IN five_CD minutes_NNS
          exposure_NN (_( Figure_NN 3_LS )_) ._.
        
        
          Effect_NN of_IN mefloquine_NN on_IN cytoplasmic_JJ calcium_NN
          homeostasis_NNS and_CC its_PRP$ antagonisation_NN by_IN thapsigargin_NN
          The_DT effect_NN of_IN mefloquine_NN on_IN whole_JJ cell_NN calcium_NN
          homeostasis_NNS was_VBD also_RB investigated_VBN ._. The_DT neurons_NNS (_( chamber_NN
          slides_NNS )_) were_VBD rinsed_JJ twice_RB with_IN fresh_JJ Locke_NNP 's_POS buffer_NN
          containing_VBG physiological_JJ levels_NNS of_IN calcium_NN (_( NaCl_NNP ,_, 154_CD mM_NN ;_:
          KCl_NNP ,_, 5_CD ._. 6_CD mM_NN ;_: NaHCO_NNP 
          3_CD ,_, 3_CD ._. 6_CD mM_NN ;_: CaCl_NNP 
          2_CD ,_, 2_CD ._. 3_CD mM_NN ;_: glucose_NN ,_, 5_CD ._. 6_CD mM_NN ;_: HEPES_NNP ,_, 5_CD
          mM_NN ;_: pH_NN 7_CD ._. 4_LS )_) and_CC immersed_VBN in_IN the_DT same_JJ solution_NN (_( 240_CD μl_NN per_IN
          chamber_NN )_) ._. Neurons_NNP were_VBD scanned_JJ at_IN 15_CD s_VBZ intervals_NNS ._.
          Mefloquine_NNP (_( 80_CD μM_NN )_) ,_, thapsigargin_NN (_( 4_CD μM_NN )_) or_CC DMSO_NNP (_( 0_CD ._. 4_LS %_NN )_)
          were_VBD added_VBN after_IN scan_VB 13_CD and_CC DMSO_NNP (_( 0_CD ._. 2_LS %_NN )_) or_CC mefloquine_NN
          (_( 80_CD μM_NN )_) after_IN scan_VB 28_CD ._.
        
        
          Detection_NNP of_IN transcriptional_NN changes_NNS in_IN key_JJ ER_NNP
          stress_NN response_NN genes_NNS using_VBG microarrays_NNS
          Neurons_NNP (_( 75_CD cm_NN 2_CD culture_NN flasks_NNS )_) were_VBD treated_VBN with_IN 0_CD ._. 2_CD %_NN
          DMSO_NNP (_( controls_NNS )_) ,_, 2_CD ,_, 10_CD or_CC 80_CD μM_NN mefloquine_NN in_IN Locke_NNP 's_POS
          buffer_NN (_( containing_VBG calcium_NN )_) for_IN five_CD minutes_NNS ._. This_DT
          treatment_NN time_NN was_VBD chosen_VBN because_IN the_DT depletion_NN of_IN the_DT ER_NNP
          calcium_NN store_NN by_IN mefloquine_NN occurs_VBZ within_IN this_DT time_NN
          period_NN ._. After_IN 5_CD min_NN ,_, the_DT media_NNS were_VBD replaced_VBN with_IN MEM_NNP
          containing_VBG 0_CD ._. 02_CD %_NN DMSO_NNP (_( for_IN the_DT control_NN ,_, 10_CD and_CC 80_CD μM_NN
          mefloquine_NN treatment_NN groups_NNS )_) or_CC 2_CD μM_NN mefloquine_NN for_IN a_DT
          further_JJ 24_CD h_NN ._. Therefore_RB ,_, neurons_NNS were_VBD exposed_VBN to_TO the_DT
          lowest_JJS mefloquine_NN concentration_NN for_IN 24_CD h_NN ._. A_DT recovery_NN
          period_NN of_IN 24_CD h_NN is_VBZ required_VBN following_VBG an_DT insult_NN with_IN an_DT
          ER-agonist_NNP to_TO induce_VB a_DT maximal_NN ER_NNP stress_NN response_NN [_NN 8_CD ]_NN ._.
          After_IN 24_CD h_NN ,_, total_JJ RNA_NNP was_VBD extracted_VBN from_IN the_DT flasks_NNS using_VBG
          RNA-STAT_NNP 60_CD as_RB previously_RB described_VBD [_NN 7_CD ]_NN ._. The_DT
          experiment_NN was_VBD repeated_VBN five_CD times_NNS on_IN independent_JJ
          occasions_NNS ._.
          Detailed_NNP procedures_NNS for_IN preparation_NN of_IN cDNA_NN and_CC
          fluorescently_RB labeled_VBN cRNA_NN ,_, hybridization_NN ,_, staining_VBG ,_, and_CC
          scanning_VBG of_IN gene_NN chips_NNS and_CC assay_NN monitoring_VBG are_VBP outlined_VBN
          in_IN earlier_JJR literature_NN [_NN 15_CD ]_NN ._. The_DT platform_NN chosen_VBN for_IN
          global_JJ expression_NN profile_NN was_VBD the_DT Rat_NNP Genome_NNP U_NNP 34_CD Array_NNP
          (_( Affymetrix_NNP ,_, Santa_NNP Clara_NNP ,_, California_NNP )_) ,_, which_WDT contains_VBZ
          probes_NNS for_IN a_DT total_NN of_IN 8799_CD expressed_VBD sequence_NN tag_NN (_( EST_NNP )_)
          clusters_NNS and_CC genes_NNS (_( including_VBG controls_NNS )_) ._. RNA_NNP (_( 10_CD μg_NN )_)
          extracted_VBN from_IN each_DT individual_JJ flask_NN was_VBD hybridized_JJ to_TO a_DT
          single_JJ gene_NN chip_NN (_( i_NNP ._. e_SYM ._. a_DT total_NN of_IN 20_CD chips_NNS were_VBD used_VBN )_) ._.
          Affymetrix_NNP analysis_NN software_NN (_( version_NN 5_LS )_) was_VBD used_VBN to_TO
          generate_VB average_JJ difference_NN (_( AD_NNP )_) values_NNS for_IN each_DT gene_NN for_IN
          each_DT treatment_NN (_( Affymetrix_NNP ,_, Santa_NNP Clara_NNP ,_, California_NNP )_) ._. AD_NNP
          values_NNS represent_VBP the_DT difference_NN in_IN mean_NN fluorescence_NN
          between_IN positive_NN and_CC mismatch_NN probe_NN cells_NNS for_IN each_DT gene_NN ,_,
          and_CC are_VBP hereafter_RB referred_VBN to_TO as_IN expression_NN values_NNS ._.
          The_DT Affymetrix_NNP website_NN http_NN :_: /_NN /_NN www_NN ._. affymetrix_NN ._. comwas_NNS
          searched_VBD using_VBG the_DT terms_NNS '_POS PEK_NNP /_NN PERK_NNP '_POS ,_, '_'' GADD_NNP 153_CD '_POS and_CC the_DT
          gene_NN names_NNS for_IN ER_NNP chaperones_NNS previously_RB identified_VBN as_IN
          being_VBG upregulated_JJ during_IN an_DT ER_NNP stress_NN response_NN [_NN 12_CD ]_NN ,_,
          and_CC where_WRB they_PRP were_VBD represented_VBN by_IN probe-sets_JJ on_IN the_DT U_NNP 34_CD
          arrays_NNS ,_, corresponding_JJ accession_NN numbers_NNS were_VBD identified_VBN ._.
          The_DT expression_NN values_NNS for_IN these_DT accession_NN numbers_NNS were_VBD
          imported_VBN directly_RB into_IN Parteck_NNP Pro_FW 2000_CD ._. No_DT additional_JJ
          data_NN normalization_NN or_CC scaling_VBG methods_NNS were_VBD employed_VBN (_( as_IN
          these_DT procedures_NNS were_VBD performed_VBN previously_RB by_IN the_DT
          Affymetrix_NNP software_NN )_) ._. One-way_NNP ANOVAs_NNP were_VBD performed_VBN to_TO
          compare_VB the_DT mean_NN expression_NN levels_NNS of_IN each_DT of_IN the_DT genes_NNS
          amongst_IN the_DT different_JJ treatment_NN groups_NNS ._. A_DT significant_JJ
          change_NN in_IN mean_NN expression_NN level_NN was_VBD assumed_VBN to_TO have_VB
          occurred_VBN where_WRB ANOVA_NNP 
          P_NN -_: values_NNS were_VBD <_NN 0_CD ._. 05_CD ._. A_DT less_RBR
          conservative_JJ significance_NN threshold_NN was_VBD considered_VBN
          appropriate_JJ since_IN the_DT total_JJ number_NN of_IN hypotheses_NNS (_( i_NNP ._. e_SYM ._.
          tests_NNS of_IN significance_NN )_) conducted_VBN was_VBD small_JJ ._. For_IN a_DT
          particular_JJ treatment_NN group_NN ,_, a_DT gene_NN was_VBD considered_VBN to_TO have_VB
          differentially_RB modulated_JJ expression_NN where_WRB the_DT fold-change_JJ
          in_IN expression_NN exceeded_VBD 1_CD ._. 3_CD ._. Fold-changes_NNP (_( FC_NNP )_) in_IN
          expression_NN were_VBD defined_VBN as_IN :_: =_SYM mean_VB mefloquine_NN expression_NN
          level_NN /_NN mean_NN DMSO_NNP expression_NN level_NN ._. Where_WRB a_DT gene_NN was_VBD
          represented_VBN by_IN more_JJR than_IN one_CD probe_NN set_VBD ,_, data_NNS is_VBZ presented_VBN
          only_RB for_IN those_DT probe-sets_JJ for_IN which_WDT the_DT ANOVA_NNP 
          P_NN -_: value_NN was_VBD <_NN 0_CD ._. 05_CD ._.
        
        
          Viability_NNP measurements_NNS
          Neuronal_NNP viability_NN was_VBD assessed_VBN using_VBG the_DT colorimetric_JJ
          MTT_NNP assay_NN as_IN described_VBN previously_RB [_NN 14_CD ]_NN ._. All_DT
          experiments_NNS were_VBD conducted_VBN in_IN Mg_NNP 2_CD +_NN -_: free_JJ Locke_NNP 's_POS solution_NN
          unless_IN otherwise_RB indicated_VBD ._. Neurons_NNP were_VBD exposed_VBN to_TO
          graded_JJ concentrations_NNS of_IN mefloquine_NN for_IN 5_CD or_CC 20_CD min_NN and_CC
          24_CD h_NN ._. After_IN treatment_NN ,_, mefloquine_NN dilutions_NNS were_VBD removed_VBN
          and_CC replaced_VBN with_IN MEM_NNP (_( Gibco_NNP )_) ._. The_DT neurons_NNS were_VBD incubated_JJ
          for_IN a_DT further_JJ 24_CD h_NN ._. The_DT next_JJ day_NN MTT_NNP was_VBD added_VBN to_TO each_DT
          well_RB such_JJ that_IN the_DT final_JJ concentration_NN of_IN the_DT dye_NN was_VBD 150_CD
          μg_NN /_NN ml_NN ._. Plates_NNP were_VBD then_RB returned_VBN to_TO the_DT incubator_NN for_IN 1_CD h_NN
          at_IN which_WDT time_NN unincorporated_JJ MTT_NNP was_VBD removed_VBN ,_, and_CC the_DT
          plates_NNS were_VBD allowed_VBN to_TO air_VB dry_JJ ._. The_DT purple_JJ formazan_NN
          product_NN indicative_JJ of_IN viable_JJ cells_NNS was_VBD then_RB dissolved_VBN by_IN
          adding_VBG 250_CD μl_NN acidified_VBN isopropanol_NN (_( 95_CD %_NN isopropanol_NN ;_: 5_CD %_NN
          2_CD N_NNP HCl_NNP )_) ,_, and_CC 200_CD μl_NN aliquots_NNS were_VBD collected_VBN ._. The_DT
          absorbance_NN of_IN these_DT aliquots_NNS was_VBD measured_VBN on_IN an_DT ELISA_NNP
          plate_NN reader_NN at_IN 540_CD nm_NN ._. The_DT effects_NNS of_IN mefloquine_NN were_VBD
          compared_VBN to_TO appropriate_JJ DMSO_NNP controls_NNS ._.
          The_DT acute_JJ toxicity_NN of_IN the_DT low_JJ calcium_NN Locke_NNP 's_POS solution_NN
          was_VBD also_RB investigated_VBN ._. Neurons_NNP were_VBD exposed_VBN to_TO the_DT buffer_NN
          at_IN 2_CD ._. 5_CD minute_NN intervals_NNS over_IN a_DT 15_CD min_NN time_NN period_NN ._.
          Effects_NNPS of_IN the_DT various_JJ treatments_NNS were_VBD compared_VBN to_TO
          appropriate_JJ controls_NNS (_( Locke_NNP 's_POS solution_NN with_IN and_CC without_IN
          calcium_NN and_CC /_NN or_CC 1_CD mM_NN EGTA_NNP for_IN 15_CD minutes_NNS )_) ._. Viability_NNP was_VBD
          assessed_VBN as_IN above_IN except_IN that_IN the_DT neurons_NNS were_VBD not_RB
          incubated_JJ overnight_JJ in_IN MEM_NNP prior_RB to_TO performing_VBG the_DT MTT_NNP
          assay_NN ._.
        
        
          Neuroprotective_NNP effect_NN of_IN thapsigargin_NN
          The_DT effect_NN of_IN mefloquine_NN (_( 10_CD or_CC 80_CD μM_NN for_IN 5_CD min_NN )_) ,_,
          before_IN and_CC after_IN pretreatment_NN with_IN thapsigargin_NN (_( 4_CD μM_NN for_IN
          5_CD min_NN )_) ,_, on_IN the_DT viability_NN of_IN rat_NN neurons_NNS was_VBD assessed_VBN as_IN
          described_VBN above_IN ._. The_DT degree_NN of_IN neuroprotection_NN afforded_VBN
          by_IN thapsigargin_NN was_VBD basically_RB the_DT extent_NN to_TO which_WDT the_DT
          drug_NN reversed_VBD the_DT decline_NN in_IN absorbance_NN (_( viability_NN )_)
          induced_VBN by_IN mefloquine_NN and_CC was_VBD calculated_VBN as_RB previously_RB
          described_VBD [_NN 14_CD ]_NN ._.
        
        
          Statistical_NNP analyses_NNS ,_, data_NNS analysis_NN and_CC
          presentation_NN
          For_IN the_DT confocal_NN experiments_NNS the_DT data_NNS are_VBP presented_VBN as_IN
          mean_NN normalized_JJ Fluo-_NNP 3_CD fluorescence_NN ±_NN the_DT standard_JJ error_NN
          of_IN the_DT mean_NN (_( SEM_NNP )_) and_CC are_VBP representative_NN of_IN at_IN least_JJS
          three_CD replicate_VB experiments_NNS ._. Toxicity_NNP and_CC neuroprotection_NN
          data_NNS are_VBP presented_VBN as_IN mean_NN (_( %_NN )_) viability_NN or_CC raw_JJ A_DT 
          540_CD values_NNS (_( ±_NN SEM_NNP )_) and_CC represent_VB the_DT
          results_NNS of_IN at_IN least_JJS three_CD experiments_NNS in_IN every_DT case_NN ._.
          Samples_NNP sizes_NNS are_VBP outlined_VBN in_IN the_DT table_NN or_CC figure_NN
          legends_NNS ._. For_IN the_DT toxicity_NN experiments_NNS ,_, the_DT significance_NN
          of_IN multiple_JJ treatments_NNS was_VBD assessed_VBN using_VBG one-way_JJ ANOVA_NNP
          and_CC Dunnett_NNP 's_POS t-test_JJ ._. For_IN the_DT neuroprotection_NN experiment_NN ,_,
          the_DT data_NNS were_VBD analyzed_VBN using_VBG a_DT two-way_JJ ANOVA_NNP ,_, with_IN a_DT 
          P_NN -_: value_NN <_NN 0_CD ._. 05_CD for_IN the_DT
          interaction_NN between_IN mefloquine_NN and_CC thapsigargin_NN taken_VBN to_TO
          represent_VB an_DT antagonistic_JJ effect_NN of_IN the_DT two_CD compounds_NNS ._.
          Statistical_NNP procedures_NNS for_IN the_DT analysis_NN of_IN microarray_NN
          data_NNS are_VBP discussed_VBN above_IN ._. Fifty_NNP percent_NN inhibitory_NN or_CC
          effective_JJ concentrations_NNS and_CC 95_CD %_NN confidence_NN intervals_NNS (_( IC_NNP
          
          50_CD or_CC ED_NNP 
          50_CD )_) for_IN the_DT effects_NNS of_IN mefloquine_NN on_IN
          neuronal_NN viability_NN and_CC calcium_NN homeostasis_NNS were_VBD
          calculated_VBN using_VBG Prism_NNP software_NN ._.
        
      
      
        Results_NNS
        
          Effects_NNPS of_IN 80_CD μM_NN mefloquine_NN on_IN ER_NNP calcium_NN
          homeostasis_NNS
          As_IN can_MD be_VB seen_VBN from_IN examination_NN of_IN the_DT first_JJ peak_NN in_IN
          Figure_NN 1_CD ,_, mefloquine_NN caused_VBD a_DT transient_JJ increase_NN in_IN
          intracellular_NN calcium_NN levels_NNS whereas_IN DMSO_NNP did_VBD not_RB ._.
          Mefloquine_NNP also_RB antagonized_JJ the_DT subsequent_JJ transient_JJ
          elevation_NN of_IN cytoplasmic_JJ calcium_NN induced_VBN by_IN the_DT addition_NN
          of_IN thapsigargin_NN as_IN can_MD be_VB seen_VBN from_IN examination_NN of_IN the_DT
          second_JJ series_NN of_IN peaks_NNS in_IN Figure_NN 1_CD ._. A_DT subsequent_JJ addition_NN
          of_IN glutamate_NN failed_VBD to_TO elicit_NN a_DT calcium_NN response_NN ,_, whereas_IN
          addition_NN of_IN calcium_NN chloride_NN to_TO the_DT medium_NN did_VBD ._. The_DT
          antagonisation_NN by_IN mefloquine_NN of_IN the_DT ER_NNP calcium_NN release_NN
          induced_VBN by_IN thapsigargin_NN ,_, a_DT specific_JJ inhibitor_NN of_IN the_DT ER_NNP
          calcium_NN pump_NN ,_, suggests_VBZ that_IN mefloquine_NN mobilizes_NNS ER_NNP
          calcium_NN stores_NNS ._. Glutamate_NNP induces_VBZ the_DT activation_NN of_IN
          plasma_NN membrane_NN influx_NN channels_NNS ,_, therefore_RB its_PRP$ failure_NN to_TO
          illicit_JJ a_DT calcium_NN response_NN shows_VBZ that_IN the_DT external_JJ media_NNS
          contained_VBD low_JJ levels_NNS of_IN free_JJ calcium_NN ._. Therefore_RB the_DT
          elevation_NN of_IN intracellular_NN calcium_NN cannot_NN be_VB attributed_VBN
          to_TO influx_NN from_IN an_DT external_JJ source_NN ._. The_DT subsequent_JJ ability_NN
          of_IN the_DT neurons_NNS to_TO elicit_NN a_DT response_NN after_IN restoration_NN of_IN
          normal_JJ levels_NNS of_IN extracellular_NN calcium_NN shows_VBZ that_IN the_DT
          neurons_NNS selected_VBN for_IN the_DT confocal_NN microscopy_NN experiments_NNS
          remained_VBD viable_JJ for_IN the_DT duration_NN of_IN these_DT
          experiments_NNS ._.
        
        
          Low-calcium_NNP Locke_NNP 's_POS buffer_NN does_VBZ not_RB substantially_RB
          reduce_VB neuronal_NN viability_NN
          The_DT neurotoxicity_NN of_IN the_DT low_JJ calcium_NN Locke_NNP 's_POS buffer_NN
          was_VBD investigated_VBN over_IN time_NN ._. As_IN can_MD be_VB seen_VBN from_IN Figure_NN 2_CD ,_,
          substitution_NN of_IN normal_JJ Locke_NNP 's_POS buffer_NN for_IN one_CD containing_VBG
          no_DT added_VBN calcium_NN results_NNS in_IN a_DT loss_NN of_IN neuronal_NN viability_NN
          (_( 27_CD %_NN reduction_NN ,_, Welch_NNP 's_POS test_NN ,_, 
          P_NN <_NN 0_CD ._. 005_CD ,_, n_NN =_SYM 8_CD )_) ._. This_DT solution_NN
          was_VBD not_RB used_VBN for_IN the_DT mefloquine_NN studies_NNS because_IN control_NN
          experiments_NNS showed_VBD that_DT glutamate_NN elicited_JJ a_DT calcium_NN
          response_NN in_IN neurons_NNS exposed_VBN to_TO this_DT buffer_NN (_( data_NNS not_RB
          shown_VBN )_) ,_, presumably_RB because_IN the_DT rinsing_VBG procedure_NN did_VBD not_RB
          remove_VB all_DT residual_JJ free_JJ calcium_NN ._. We_PRP utilized_JJ a_DT low_JJ
          calcium_NN (_( 920_CD μM_NN )_) Locke_NNP 's_POS buffer_NN supplemented_JJ with_IN EGTA_NNP (_( 1_CD
          mM_NN )_) for_IN the_DT confocal_NN microscopy_NN experiments_NNS ._. As_IN can_MD be_VB
          seen_VBN from_IN Figure_NN 2_CD ,_, exposure_NN to_TO this_DT buffer_NN for_IN 10_CD
          minutes_NNS was_VBD required_VBN to_TO reduce_VB the_DT viability_NN of_IN the_DT
          neurons_NNS below_IN that_DT induced_VBN by_IN treatment_NN of_IN neurons_NNS with_IN
          Locke_NNP 's_POS containing_VBG no_DT added_VBN calcium_NN (_( one_CD way_NN ANOVA_NNP and_CC
          Dunnett_NNP 's_POS test_NN ,_, 
          P_NN <_NN 0_CD ._. 05_CD ,_, n_NN =_SYM 44_CD )_) ._. All_DT
          mefloquine_NN calcium_NN response_NN experiments_NNS were_VBD conducted_VBN
          within_IN this_DT time_NN frame_NN ,_, and_CC care_NN was_VBD taken_VBN to_TO analyze_VB
          data_NNS only_RB from_IN neurons_NNS that_WDT were_VBD shown_VBN to_TO be_VB viable_JJ at_IN
          the_DT termination_NN of_IN the_DT experiment_NN (_( as_IN indicated_VBN by_IN the_DT
          CaCl_NNP 
          2_CD -_: induced_VBN calcium_NN response_NN )_) ._.
        
        
          Effect_NN of_IN lower_JJR mefloquine_NN concentrations_NNS on_IN ER_NNP
          calcium_NN homeostasis_NNS and_CC relationship_NN to_TO time-dependent_JJ
          neurotoxicity_NN
          We_PRP next_RB investigated_VBD the_DT effects_NNS of_IN lower_JJR mefloquine_NN
          doses_NNS on_IN neuronal_NN ER_NNP calcium_NN homeostasis_NNS (_( i_NNP ._. e_SYM ._. in_IN
          low-calcium_JJ Locke_NNP 's_POS buffer_NN )_) ._. At_IN concentrations_NNS of_IN at_IN
          least_JJS 30_CD μM_NN ,_, mefloquine_NN induced_VBD a_DT transient_JJ increase_NN in_IN
          cytosolic_JJ calcium_NN levels_NNS (_( Table_NNP 1_CD ,_, one-way_JJ ANOVA_NNP ,_,
          Dunnett_NNP 's_POS t-test_JJ ,_, 
          P_NN <_NN 0_CD ._. 05_CD ,_, 
          n_NN =_SYM 29_CD )_) ._. The_DT effect_NN was_VBD
          dose-related_JJ ,_, with_IN an_DT ED_NNP 
          50_CD of_IN 66_CD μM_NN (_( 95_CD %_NN confidence_NN interval_NN ,_,
          33_CD -_: 130_CD μM_NN )_) ._. The_DT IC_NNP 
          50_CD of_IN mefloquine_NN 's_POS effect_NN on_IN neuronal_NN
          viability_NN after_IN 5_CD min_NN exposure_NN was_VBD 62_CD (_( 19_CD -_: 204_CD )_) μM_NN ,_, and_CC
          the_DT dose_NN response_NN curves_NNS of_IN the_DT two_CD effects_NNS are_VBP
          super-imposable_JJ (_( Figure_NN 3_LS )_) ._. These_DT data_NNS suggest_VBP that_IN the_DT
          two_CD effects_NNS may_MD be_VB related_VBN ._. The_DT IC_NNP 
          50_CD s_VBZ of_IN mefloquine_NN 's_POS effect_NN on_IN
          neuronal_NN viability_NN were_VBD 23_CD (_( 18_CD -_: 28_CD )_) and_CC 19_CD (_( 11_CD -_: 32_CD )_) μM_NN for_IN
          exposure_NN times_NNS 20_CD min_NN and_CC 24_CD h_NN respectively_RB ._. The_DT
          concentration-effect_JJ curves_NNS are_VBP super-imposable_JJ ._. Also_RB ,_, at_IN
          a_DT concentration_NN of_IN 50_CD μM_NN ,_, mefloquine_NN exhibited_VBN a_DT greater_JJR
          neurotoxic_JJ effect_NN after_IN 20_CD min_NN or_CC 24_CD h_NN exposure_NN as_IN
          compared_VBN to_TO a_DT 5_CD minute_NN exposure_NN (_( one_CD way_NN ANOVA_NNP and_CC
          Dunnett_NNP 's_POS t-test_JJ ,_, 
          P_NN <_NN 0_CD ._. 0001_CD ,_, n_NN =_SYM 12_CD )_) ._. Therefore_RB ,_,
          it_PRP appears_VBZ that_IN most_JJS of_IN mefloquine_NN 's_POS neurotoxic_JJ effects_NNS
          occur_VBP within_IN 20_CD min_NN of_IN exposure_NN ,_, but_CC cannot_NN be_VB accounted_VBN
          for_IN solely_RB by_IN the_DT disruptive_JJ effect_NN of_IN mefloquine_NN on_IN ER_NNP
          calcium_NN homeostasis_NNS ._. Consequently_RB ,_, we_PRP investigated_VBD the_DT
          effect_NN of_IN mefloquine_NN on_IN neuronal_NN calcium_NN homeostasis_NNS in_IN
          calcium-containing_JJ media_NNS ._.
        
        
          Effect_NN of_IN mefloquine_NN on_IN whole_JJ cell_NN calcium_NN
          homeostasis_NNS
          The_DT effects_NNS of_IN mefloquine_NN on_IN neuronal_NN calcium_NN
          homeostasis_NNS in_IN calcium-containing_JJ medium_NN were_VBD
          investigated_VBN ._. As_IN shown_VBN in_IN Figure_NN 4_CD ,_, mefloquine_NN (_( 80_CD μM_NN )_)
          caused_VBD an_DT immediate_JJ and_CC sustained_VBN rise_NN in_IN cytoplasmic_JJ
          calcium_NN levels_NNS ._. In_IN some_DT experiments_NNS ,_, this_DT sustained_JJ
          elevation_NN of_IN cytoplasmic_JJ calcium_NN was_VBD preceded_VBN by_IN a_DT
          transient_JJ rise_NN as_IN observed_VBN in_IN low_JJ calcium_NN Locke_NNP 's_POS (_( as_IN in_IN
          Figure_NN 1_LS )_) ._. The_DT sustained_VBN elevation_NN of_IN cytoplasmic_JJ calcium_NN
          can_MD only_RB be_VB due_JJ to_TO entry_NN from_IN an_DT external_JJ source_NN ,_, as_IN it_PRP
          was_VBD not_RB observed_VBN in_IN the_DT low-calcium_JJ medium_NN ._.
        
        
          Thapsigargin_NNP antagonizes_NNS the_DT disruptive_JJ effect_NN of_IN
          mefloquine_NN on_IN calcium_NN homeostasis_NNS and_CC protects_VBZ neurons_NNS
          from_IN cellular_JJ injury_NN
          Pre-treatment_NNP with_IN thapsigargin_NN (_( 4_CD μM_NN )_) antagonised_JJ
          both_DT the_DT initial_JJ rise_NN in_IN intracellular_NN calcium_NN
          attributable_JJ to_TO the_DT effect_NN of_IN mefloquine_NN on_IN the_DT ER_NNP
          calcium_NN store_NN ,_, and_CC the_DT subsequent_JJ sustained_VBN influx_NN of_IN
          external_JJ calcium_NN (_( Figure_NN 4_LS )_) ._. We_PRP next_RB investigated_VBD the_DT
          possibility_NN that_DT thapsigargin_NN pretreatment_NN might_MD have_VB a_DT
          protective_JJ effect_NN on_IN neurons_NNS exposed_VBN to_TO mefloquine_NN ._. Rat_NNP
          neurons_NNS were_VBD pretreated_JJ with_IN either_DT thapsigargin_NN (_( 4_CD μM_NN )_)
          or_CC DMSO_NNP (_( 0_CD ._. 4_LS %_NN )_) for_IN 5_CD min_NN prior_RB to_TO the_DT addition_NN of_IN DMSO_NNP
          (_( 0_CD ._. 2_LS %_NN )_) or_CC mefloquine_NN (_( 10_CD or_CC 80_CD μM_NN )_) for_IN 5_CD min_NN ._. The_DT drugs_NNS
          were_VBD then_RB removed_VBN and_CC incubated_JJ in_IN calcium-containing_JJ MEM_NNP
          medium_NN for_IN 24_CD h_NN prior_RB to_TO viability_NN assessment_NN using_VBG the_DT
          MTT_NNP assay_NN ._. As_IN can_MD be_VB seen_VBN in_IN Figure_NN 5_CD ,_, pretreatment_NN with_IN
          thapsigargin_NN reduced_VBD the_DT decline_NN in_IN viability_NN
          (_( absorbance_NN )_) induced_VBN by_IN mefloquine_NN by_IN 60_CD %_NN ._. There_EX was_VBD a_DT
          significant_JJ interaction_NN between_IN thapsigargin_NN and_CC
          mefloquine_NN ,_, indicating_VBG that_IN the_DT drugs_NNS behave_VB
          antagonistically_RB (_( two_CD way_NN ANOVA_NNP ,_, 
          P_NN <_NN 0_CD ._. 0001_CD ,_, n_NN =_SYM 48_CD )_) ._.
        
        
          Mefloquine_NNP upregulates_NNS the_DT transcription_NN of_IN
          important_JJ ER_NNP stress_NN response_NN genes_NNS
          The_DT Rat_NNP Genome_NNP U_NNP 34_CD array_NN was_VBD found_VBN to_TO contain_VB
          probe-sets_JJ representing_VBG the_DT ER_NNP chaperones_NNS
          glucose-regulated_JJ protein_NN (_( GRP_NNP )_) 78_CD ,_, protein_NN disulfide_NN
          isomerase_NN ,_, GRP_NNP 94_CD ,_, calreticulin_NN and_CC endoplasmic_JJ reticulum_NN
          protein_NN 29_CD (_( EPR_NNP 29_CD )_) ,_, GADD_NNP 153_CD and_CC PERK_NNP ._. Mefloquine_NNP (_( 80_CD μM_NN )_)
          upregulated_JJ the_DT transcription_NN of_IN four_CD of_IN five_CD ER_NNP resident_NN
          chaperones_NNS ,_, GRP_NNP 78_CD ,_, PDI_NNP ,_, GRP_NNP 94_CD and_CC calreticulin_NN ,_, GADD_NNP 153_CD
          and_CC PERK_NNP (_( one_CD way_NN ANOVA_NNP 
          P_NN <_NN 0_CD ._. 05_CD ,_, n_NN =_SYM 20_CD ,_, FC_NNP >_NN 1_CD ._. 3_CD ,_,
          Table_NNP 2_LS )_) ._. Mefloquine_NNP induced_VBD no_DT transcriptional_NN changes_NNS
          at_IN 2_CD μM_NN (_( 24_CD h_NN )_) or_CC 10_CD μM_NN (_( 5_CD min_NN )_) ._. Relative_NNP transcriptional_NN
          changes_NNS at_IN each_DT concentration_NN for_IN GRP_NNP 78_CD ,_, GADD_NNP 153_CD and_CC PERK_NNP
          are_VBP shown_VBN in_IN Figure_NN 6_CD ._. Mefloquine_NNP induced_VBD no_DT significant_JJ
          change_NN in_IN the_DT levels_NNS of_IN λ-tubulin_JJ mRNA_NN (_( Table_NNP 2_CD ,_, Figure_NN
          6_CD )_) ._. λ-tubulin_JJ was_VBD called_VBN present_JJ by_IN Affymetrix_NNP software_NN
          in_IN all_DT 20_CD samples_NNS (_( mean_VB 
          P_NN =_SYM 0_CD ._. 00106_CD )_) ,_, and_CC the_DT mean_JJ control_NN
          (_( DMSO_NNP )_) AD_NNP (_( ±_NN SEM_NNP )_) value_NN was_VBD 444_CD (_( ±_NN 88_CD )_) ._.
        
      
      
        Discussion_NNP
        There_EX are_VBP relatively_RB few_JJ studies_NNS that_WDT have_VBP attempted_VBN to_TO
        address_VB the_DT possibility_NN that_IN a_DT biochemical_JJ explanation_NN may_MD
        lie_VB behind_IN the_DT neurotoxicity_NN of_IN mefloquine_NN ._. However_RB ,_,
        previous_JJ literature_NN suggested_VBD that_DT mefloquine_NN might_MD disrupt_VB
        ER_NNP calcium_NN homeostasis_NNS ._. Firstly_NNP ,_, Go_NNP and_CC others_NNS [_NN 5_CD 6_CD ]_NN
        showed_VBD that_IN mefloquine_NN alters_NNS calcium_NN flux_NN into_IN and_CC out_IN of_IN
        isolated_VBN mammalian_JJ microsomes_NNS obtained_VBN from_IN skeletal_NN muscle_NN
        and_CC neuronal_NN tissue_NN ._. Secondly_RB ,_, mefloquine_NN has_VBZ been_VBN shown_VBN to_TO
        cause_VB a_DT striking_JJ upregulation_NN of_IN GADD_NNP 153_CD ,_, a_DT transcription_NN
        factor_NN selectively_RB modulated_JJ under_IN conditions_NNS of_IN ER_NNP stress_NN
        [_NN 8_CD ]_NN ._. However_RB ,_, the_DT depletion_NN of_IN the_DT ER_NNP calcium_NN pool_NN on_IN
        the_DT one_CD hand_NN ,_, and_CC a_DT consequent_JJ induction_NN of_IN an_DT ER_NNP stress_NN
        response_NN have_VBP not_RB been_VBN shown_VBN to_TO occur_VB simultaneously_RB in_IN
        intact_JJ primary_JJ neurons_NNS ._. In_IN the_DT present_JJ study_NN ,_, utilizing_VBG
        confocal_NN microscopy_NN and_CC Affymetrix_NNP arrays_NNS ,_, we_PRP have_VBP shown_VBN
        that_IN at_IN least_JJS one_CD component_NN of_IN the_DT neurotoxicity_NN of_IN
        mefloquine_NN can_MD be_VB attributed_VBN to_TO an_DT effect_NN on_IN the_DT ER_NNP calcium_NN
        store_NN ,_, and_CC that_IN the_DT drug_NN activates_NNS a_DT UPR_NNP similar_JJ to_TO that_DT
        induced_VBN by_IN agents_NNS known_VBN to_TO disrupt_VB ER_NNP function_NN ._.
        We_PRP employed_VBN confocal_NN microscopy_NN as_IN a_DT tool_NN to_TO investigate_VB
        the_DT effects_NNS of_IN mefloquine_NN on_IN calcium_NN homeostasis_NNS ._. This_DT
        approach_NN has_VBZ an_DT advantage_NN over_IN that_DT employed_VBN by_IN Go_VB et_CC al_NN [_NN
        6_CD ]_NN ,_, in_IN that_DT calcium_NN homeostasis_NNS can_MD be_VB assessed_VBN in_IN
        real-time_JJ in_IN live_VB ,_, intact_JJ neurons_NNS ._. Our_PRP$ data_NNS show_VBP that_IN ,_, in_IN
        nominally_RB calcium_NN free_JJ medium_NN ,_, mefloquine_NN induces_VBZ a_DT
        transitory_JJ elevation_NN of_IN cytoplasmic_JJ calcium_NN levels_NNS and_CC
        antagonizes_NNS a_DT similar_JJ effect_NN induced_VBN by_IN thapsigargin_NN ._. The_DT
        most_RBS reasonable_JJ interpretation_NN of_IN these_DT data_NNS is_VBZ that_IN
        mefloquine_NN mobilizes_NNS a_DT thapsigargin-sensitive_JJ calcium_NN pool_NN ,_,
        and_CC ,_, since_IN thapsigargin_NN is_VBZ known_VBN to_TO mobilize_VB the_DT ER_NNP calcium_NN
        pool_NN ,_, that_IN this_DT is_VBZ also_RB the_DT case_NN for_IN mefloquine_NN ._. The_DT ER_NNP
        calcium_NN pool_NN can_MD be_VB mobilized_VBN in_IN two_CD ways_NNS ._. Firstly_NNP ,_, an_DT
        inhibitory_NN effect_NN of_IN an_DT ER-active_NNP agent_NN (_( e_SYM ._. g_SYM ._. thapsigargin_NN )_)
        on_IN the_DT ER_NNP Ca_NNP 2_CD +_NN -_: ATPase_NNP results_NNS in_IN a_DT decrease_NN in_IN the_DT rate_NN of_IN
        calcium_NN influx_NN across_IN the_DT ER_NNP membrane_NN ._. As_IN a_DT consequence_NN of_IN
        a_DT passive_JJ leak_NN of_IN calcium_NN ions_NNS across_IN the_DT ER_NNP membrane_NN into_IN
        the_DT cytoplasm_NN ,_, the_DT store_NN becomes_VBZ depleted_VBN and_CC a_DT transient_JJ
        elevation_NN in_IN the_DT cytoplasmic_JJ calcium_NN concentration_NN occurs_VBZ ._.
        Alternatively_RB ,_, some_DT ER-active_NNP agents_NNS (_( e_SYM ._. g_SYM ._. ryanodine_NN )_)
        deplete_VB the_DT calcium_NN store_NN by_IN activating_VBG calcium_NN release_NN
        channels_NNS ._. Either_CC of_IN these_DT effects_NNS could_MD account_VB for_IN our_PRP$
        observations_NNS ._.
        Compromised_NNP ER_NNP function_NN (_( induced_VBN by_IN numerous_JJ stressors_NNS
        including_VBG depletion_NN of_IN ER_NNP calcium_NN stores_NNS )_) may_MD lead_VB to_TO the_DT
        accumulation_NN of_IN unfolded_VBD proteins_NNS in_IN the_DT ER_NNP [_NN 11_CD ]_NN ._. These_DT
        events_NNS may_MD trigger_VB the_DT UPR_NNP ,_, in_IN which_WDT the_DT transcription_NN of_IN
        genes_NNS encoding_VBG ER-resident_NNP chaperones_NNS is_VBZ upregulated_JJ ._. The_DT
        ability_NN of_IN mefloquine_NN to_TO upregulate_NN the_DT transcription_NN of_IN
        PDI_NNP ,_, GRP_NNP 78_CD ,_, GRP_NNP 94_CD and_CC calreticulin_NN is_VBZ consistent_JJ with_IN this_DT
        hypothesis_NNS ._. Triggering_VBG of_IN the_DT UPR_NNP also_RB results_VBZ in_IN the_DT
        suppression_NN of_IN global_JJ protein_NN synthesis_NN ,_, as_IN PERK_NNP is_VBZ
        activated_VBN and_CC phosphorylates_NNS EIK_NNP 2_CD α_NN ,_, which_WDT can_MD only_RB interact_NN
        with_IN the_DT appropriate_JJ ribosomal_JJ binding_JJ sites_NNS in_IN an_DT
        unphosphorylated_JJ state_NN [_NN 11_CD 12_CD ]_NN ._. While_IN the_DT upregulated_JJ
        transcription_NN of_IN PERK_NNP is_VBZ not_RB required_VBN for_IN its_PRP$ activation_NN ,_,
        it_PRP 's_VBZ over_IN expression_NN can_MD lead_VB to_TO the_DT enhanced_JJ
        phosphorylation_NN (_( and_CC therefore_RB inactivity_NN )_) of_IN EIK_NNP 2_CD α_NN [_NN 16_CD ]_NN
        ._. Therefore_RB ,_, its_PRP$ up-regulation_JJ by_IN mefloquine_NN supports_VBZ the_DT
        hypothesis_NNS that_IN the_DT drug_NN triggers_VBZ an_DT UPR_NNP ._. The_DT third_JJ
        component_NN to_TO the_DT UPR_NNP cascade_NN is_VBZ an_DT induction_NN of_IN the_DT ER_NNP
        transcription_NN factor_NN GADD_NNP 153_CD [_NN 11_CD 12_CD ]_NN ,_, an_DT effect_NN also_RB
        observed_VBD after_IN mefloquine_NN treatment_NN ._. Thus_RB it_PRP appears_VBZ that_DT
        mefloquine_NN induces_VBZ an_DT UPR_NNP similar_JJ to_TO that_DT induced_VBN by_IN agents_NNS
        (_( e_SYM ._. g_SYM ._. thapsigargin_NN )_) known_VBN to_TO cause_VB ER_NNP stress_NN [_NN 8_CD ]_NN ._.
        The_DT effects_NNS of_IN mefloquine_NN on_IN ER_NNP calcium_NN homeostasis_NNS have_VBP
        been_VBN examined_VBN previously_RB [_NN 5_CD 6_CD ]_NN ._. In_IN experiments_NNS with_IN
        isolated_VBN rabbit_NN skeletal_NN muscle_NN microsomes_NNS ,_, mefloquine_NN was_VBD
        found_VBN to_TO inhibit_VB the_DT uptake_NN of_IN calcium_NN ,_, with_IN an_DT IC_NNP 
        50_CD of_IN approximately_RB 43_CD μM_NN [_NN 6_CD ]_NN ._. This_DT
        effect_NN was_VBD exacerbated_VBN by_IN treatment_NN with_IN thapsigargin_NN ,_, a_DT
        specific_JJ inhibitor_NN of_IN the_DT ER_NNP calcium_NN pump_NN [_NN 6_CD ]_NN ._. Further_RB ,_,
        the_DT rate_NN of_IN ATP_NNP hydrolysis_NNS by_IN the_DT ER_NNP Ca_NNP 2_CD +_NN -_: ATPase_NNP was_VBD
        reduced_VBN in_IN the_DT presence_NN of_IN mefloquine_NN (_( Ki_NNP of_IN =_SYM 53_CD μM_NN )_) ._.
        These_DT authors_NNS concluded_VBD that_IN the_DT ER_NNP calcium_NN pump_NN might_MD be_VB a_DT
        target_NN of_IN mefloquine_NN ._. As_IN discussed_VBN above_IN ,_, our_PRP$ own_JJ data_NNS are_VBP
        also_RB consistent_JJ with_IN such_JJ a_DT mechanism_NN ._. The_DT observation_NN by_IN
        Go_VB et_CC al_NN ._. [_NN 6_CD ]_NN ,_, that_IN the_DT effects_NNS of_IN mefloquine_NN and_CC
        thapsigargin_NN on_IN microsomal_NN calcium_NN uptake_NN are_VBP synergistic_JJ ,_,
        might_MD seem_VB at_IN first_JJ to_TO contradict_VB ours_PRP ._. However_RB ,_, it_PRP should_MD
        be_VB pointed_VBN out_RP that_IN in_IN our_PRP$ study_NN ,_, we_PRP treated_VBD neurons_NNS with_IN
        these_DT two_CD agents_NNS sequentially_RB ,_, so_IN that_RB ,_, in_IN effect_NN ,_, one_CD of_IN
        the_DT agents_NNS was_VBD acting_VBG on_IN a_DT depleted_VBN ER_NNP calcium_NN pool_NN ._. Under_IN
        the_DT conditions_NNS employed_VBN in_IN our_PRP$ study_NN ,_, it_PRP is_VBZ not_RB surprising_JJ
        that_DT mefloquine_NN antagonized_JJ the_DT effect_NN of_IN thapsigargin_NN ._.
        Li_NNP et_CC al_NN [_NN 5_CD ]_NN also_RB found_VBD that_DT mefloquine_NN inhibited_VBD
        calcium_NN uptake_NN into_IN isolated_VBN microsomes_NNS from_IN dog_NN brain_NN
        neurons_NNS -_: presumably_RB via_IN the_DT same_JJ mechanism_NN -_: although_IN the_DT
        drug_NN was_VBD much_RB less_RBR potent_JJ (_( IC_NNP 
        50_CD of_IN 272_CD μM_NN )_) than_IN we_PRP are_VBP reporting_VBG it_PRP
        to_TO be_VB ._. We_PRP observed_VBD an_DT approximately_RB four-fold_RB more_RBR potent_JJ
        effect_NN of_IN mefloquine_NN on_IN ER_NNP calcium_NN homeostasis_NNS in_IN rat_NN
        neurons_NNS (_( IC_NNP 
        50_CD of_IN 66_CD μM_NN )_) ._. It_PRP would_MD be_VB tempting_JJ to_TO
        speculate_VB that_RB ,_, because_IN mefloquine_NN 's_POS effects_NNS on_IN rat_NN
        neuronal_NN ER_NNP calcium_NN homeostasis_NNS were_VBD more_RBR potent_JJ than_IN that_DT
        for_IN dog-brain_JJ microsomes_NNS ,_, there_EX might_MD exist_VB a_DT species_NNS
        difference_NN in_IN sensitivity_NN to_TO the_DT drug_NN ._. However_RB ,_, this_DT would_MD
        be_VB premature_JJ ,_, since_IN the_DT two_CD studies_NNS have_VBP employed_VBN markedly_RB
        different_JJ experimental_JJ systems_NNS to_TO observe_VB similar_JJ
        phenomena_NNS ._. Li_NNP et_CC al_NN ._. also_RB observed_VBD that_DT mefloquine_NN
        inhibited_VBD IP_NNP 
        3_CD -_: induced_VBN calcium_NN release_NN from_IN isolated_VBN
        dog_NN brain_NN microsomes_NNS [_NN 5_CD ]_NN ._. Our_PRP$ results_NNS do_VBP not_RB preclude_VB
        such_PDT a_DT role_NN for_IN mefloquine_NN in_IN neuronal_NN cells_NNS ,_, although_IN it_PRP
        would_MD not_RB have_VB been_VBN possible_JJ to_TO observe_VB such_JJ an_DT effect_NN in_IN
        the_DT present_JJ study_NN ,_, since_IN we_PRP investigated_VBD only_RB the_DT
        spontaneous_JJ action_NN of_IN mefloquine_NN on_IN ER_NNP calcium_NN
        homeostasis_NNS ._.
        Mefloquine_NNP 's_POS disruption_NN of_IN ER_NNP calcium_NN homeostasis_NNS may_MD
        contribute_VB to_TO the_DT acute_JJ neurotoxicity_NN of_IN the_DT drug_NN ,_, since_IN
        the_DT concentration-response_JJ for_IN these_DT effects_NNS are_VBP
        superimposable_JJ over_IN the_DT same_JJ time_NN frame_NN (_( 5_CD minutes_NNS )_) ._.
        However_RB ,_, the_DT toxicity_NN of_IN the_DT drug_NN is_VBZ somewhat_RB
        time-dependent_JJ ,_, since_IN the_DT magnitude_NN of_IN its_PRP$ effect_NN is_VBZ
        greater_JJR after_IN twenty_CD minutes_NNS exposure_NN as_IN compared_VBN to_TO five_CD
        minutes_NNS ._. We_PRP also_RB investigated_VBD mefloquine_NN 's_POS effects_NNS in_IN
        calcium-containing_JJ medium_NN and_CC found_VBD that_IN the_DT drug_NN induces_VBZ a_DT
        sustained_VBN secondary_JJ rise_NN in_IN cytoplasmic_JJ calcium_NN originating_VBG
        from_IN an_DT external_JJ source_NN ._. Thapsigargin_NNP blocked_VBD both_DT the_DT
        initial_JJ and_CC secondary_JJ rises_NNS in_IN cytoplasmic_JJ calcium_NN induced_VBN
        by_IN mefloquine_NN and_CC partially_RB reversed_VBD the_DT neurotoxicity_NN of_IN
        the_DT drug_NN ._. These_DT observations_NNS are_VBP suggestive_JJ of_IN two_CD things_NNS ._.
        Firstly_NNP ,_, the_DT trigger_NN for_IN the_DT sustained_VBN elevation_NN in_IN
        cytoplasmic_JJ calcium_NN may_MD occur_VB at_IN the_DT level_NN of_IN the_DT ER_NNP ,_, and_CC
        secondly_RB ,_, this_DT effect_NN may_MD also_RB contribute_VB substantially_RB to_TO
        the_DT neurotoxicity_NN of_IN mefloquine_NN ._. However_RB ,_, the_DT molecular_JJ
        basis_NN for_IN these_DT two_CD events_NNS is_VBZ unclear_JJ ._. It_PRP is_VBZ possible_JJ that_DT
        mefloquine_NN induces_VBZ store-mediated_JJ capacitative_JJ calcium_NN
        entry_NN [_NN see_VB reference_NN [_NN 17_CD ]_NN ]_NN ._. However_RB ,_, it_PRP is_VBZ unclear_JJ why_WRB
        thapsigargin_NN ,_, which_WDT also_RB depletes_VBZ the_DT ER_NNP calcium_NN store_NN ,_,
        would_MD not_RB produce_VB a_DT similar_JJ effect_NN ._. Our_PRP$ laboratory_NN is_VBZ
        currently_RB investigating_VBG the_DT possibility_NN that_WDT known_VBN
        inhibitors_NNS of_IN store-mediated_JJ calcium_NN entry_NN (_( e_SYM ._. g_SYM ._. non_NN
        hydrolysable_JJ GTP_NNP analogs_NNS and_CC SKF_NNP 96365_CD )_) might_MD also_RB block_VB the_DT
        effects_NNS of_IN mefloquine_NN ._.
        Mefloquine_NNP use_NN has_VBZ been_VBN associated_VBN with_IN two_CD broad_JJ
        classes_NNS of_IN neurological_JJ disorders_NNS :_: (_( i_NNP )_) central_JJ and_CC
        peripheral_JJ nervous_JJ system_NN disorders_NNS including_VBG headache_NN ,_,
        dizziness_NN ,_, vertigo_NN and_CC seizures_NNS and_CC (_( ii_NN )_) psychiatric_JJ events_NNS
        including_VBG insomnia_NN ,_, anxiety_NN ,_, affective_JJ and_CC major_JJ disorders_NNS
        [_NN 2_CD ]_NN ._. It_PRP is_VBZ well_RB known_VBN and_CC has_VBZ been_VBN accepted_VBN for_IN some_DT
        time_NN that_IN prolonged_JJ disruptions_NNS in_IN Ca_MD 2_CD +_NN homeostasis_NNS can_MD
        result_VB in_IN impairment_NN of_IN neuronal_NN function_NN and_CC cell_NN death_NN [_NN
        18_CD 19_CD ]_NN ._. Impairment_NNP or_CC loss_NN of_IN neurons_NNS in_IN specific_JJ regions_NNS
        of_IN the_DT brain_NN might_MD be_VB manifested_JJ in_IN symptoms_NNS reported_VBD to_TO
        have_VB occurred_VBN in_IN patients_NNS treated_VBN with_IN mefloquine_NN ._. For_IN
        example_NN ,_, the_DT vertigo_NN reported_VBN by_IN some_DT patients_NNS might_MD be_VB
        attributable_JJ to_TO neuronal_NN death_NN in_IN the_DT inferior_JJ cerebellum_NN [_NN
        20_CD ]_NN ,_, whereas_IN symptoms_NNS of_IN fear_NN /_NN anxiety_NN might_MD arise_VB as_IN a_DT
        consequence_NN of_IN the_DT death_NN of_IN neurons_NNS in_IN the_DT amygdala_NN [_NN 21_CD ]_NN
        ._. Mefloquine-induced_NNP neurotoxicity_NN in_IN the_DT limbic_JJ system_NN
        might_MD be_VB responsible_JJ for_IN reported_VBD disturbances_NNS in_IN emotion_NN [_NN
        22_CD ]_NN ._.
        Mefloquine_NNP accumulates_NNS to_TO plasma_NN concentrations_NNS of_IN 3_CD ._. 8_CD
        and_CC 2_CD ._. 1_CD -_: 23_CD μM_NN after_IN administration_NN at_IN prophylactic_JJ dose_NN and_CC
        therapeutic_JJ dosing_VBG respectively_RB [_NN 3_CD 4_CD ]_NN ._. Therefore_RB ,_, only_RB
        at_IN the_DT time_NN of_IN peak_NN plasma_NN concentrations_NNS in_IN a_DT few_JJ
        patients_NNS ,_, do_VBP mefloquine_NN plasma_NN concentrations_NNS approach_VBP the_DT
        threshold_NN necessary_JJ (_( >_NN 10_CD μM_NN )_) to_TO induce_VB any_DT of_IN the_DT
        effects_NNS observed_VBD in_IN the_DT present_JJ study_NN ._. However_RB ,_, in_IN human_JJ
        post-mortem_JJ cases_NNS ,_, mefloquine_NN has_VBZ been_VBN found_VBN to_TO accumulate_VBP
        in_IN the_DT brain_NN relative_JJ to_TO plasma_NN by_IN as_RB much_JJ as_IN 30_CD -_: fold_VB ,_, with_IN
        absolute_JJ ,_, equivalent_NN concentrations_NNS exceeding_VBG 50_CD μM_NN (_( Table_NNP
        3_LS )_) ._. These_DT observations_NNS have_VBP been_VBN confirmed_VBN in_IN rats_NNS ,_, where_WRB
        the_DT accumulation_NN was_VBD found_VBN to_TO be_VB 12_CD ._. 5_LS -_: fold_VB with_IN absolute_JJ ,_,
        equivalent_NN concentrations_NNS exceeding_VBG 90_CD μM_NN (_( Table_NNP 3_LS )_) ._. Thus_RB ,_,
        mefloquine_NN apparently_RB crosses_VBZ the_DT blood-brain_JJ barrier_NN and_CC
        accumulates_NNS to_TO sufficient_JJ levels_NNS to_TO include_VB those_DT
        concentrations_NNS found_VBD to_TO disrupt_VB neuronal_NN calcium_NN
        homeostasis_NNS and_CC ER_NNP function_NN 
        in_IN vitro_NN ._. The_DT possibility_NN that_IN a_DT
        disruption_NN of_IN neuronal_NN calcium_NN homeostasis_NNS or_CC ER_NNP function_NN
        may_MD be_VB responsible_JJ ,_, at_IN least_JJS in_IN part_NN ,_, for_IN the_DT clinical_JJ
        neurotoxicity_NN of_IN mefloquine_NN is_VBZ worthy_JJ of_IN further_JJ
        investigation_NN ._.
      
      
        Conclusion_NNP
        Mefloquine_NNP was_VBD found_VBN to_TO disrupt_VB calcium_NN homeostasis_NNS in_IN
        rat_NN neurons_NNS by_IN mobilizing_VBG the_DT ER_NNP calcium_NN pool_NN and_CC inducing_VBG
        a_DT sustained_VBN elevation_NN of_IN cytoplasmic_JJ calcium_NN originating_VBG
        from_IN an_DT external_JJ source_NN ._. Mefloquine_NNP also_RB induced_VBD a_DT
        characteristic_JJ ER_NNP stress_NN response_NN ._. The_DT effects_NNS were_VBD
        observed_VBN at_IN physiologically_RB relevant_JJ concentrations_NNS and_CC may_MD
        contribute_VB to_TO the_DT acute_JJ neurotoxicity_NN of_IN the_DT drug_NN 
        in_IN vitro_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
    
  
